A Swedish study found that systemic lupus erythematosus patients who fail to respond to standard therapy may benefit from a combination of rituximab, which targets the immune system's B cells, and cyclophosphamide, an immune suppressant. Researchers reported that most SLE patients showed at least a 50% improvment in disease severity while some experienced remission.

Full Story:

Related Summaries